Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirivadelgat in Fanconi Anemia
NCT04522375Phase 2Withdrawn
- Sponsor
- Foresee Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mirivadelgat in Fanconi anemia (FA), sponsored by Foresee Pharmaceuticals. Planned start Jun 2023; status: withdrawn.
02
Drugs
mirivadelgat
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT04522375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522375.